SI2176220T1 - Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev - Google Patents

Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev

Info

Publication number: SI2176220T1
Authority: SI; Slovenia
Prior art keywords: pyrrolidin; derivatives; androgen receptor; receptor modulators; modulators
Prior art date: 2007-08-07

Application number

SI200830941T

Other languages

English (en)

Inventor

Atsushi Hasuoka

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-07

Filing date

2008-08-06

Publication date

2013-05-31

2008-08-06 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2013-05-31 Publication of SI2176220T1 publication Critical patent/SI2176220T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

SI200830941T 2007-08-07 2008-08-06 Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev SI2176220T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2007205966		2007-08-07
JP2007299658		2007-11-19
PCT/JP2008/064500 WO2009020234A2 (en)	2007-08-07	2008-08-06	Pyrrolidin-2 -one derivatives as androgen receptor modulator
EP08792430A EP2176220B1 (en)	2007-08-07	2008-08-06	Pyrrolidin-2-one derivatives as androgen receptor modulators

Publications (1)

Publication Number	Publication Date
SI2176220T1 true SI2176220T1 (sl)	2013-05-31

Family

ID=40329363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200830941T SI2176220T1 (sl)	2007-08-07	2008-08-06	Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev

Country Status (34)

Country	Link
US (2)	US8420694B2 (sl)
EP (1)	EP2176220B1 (sl)
JP (1)	JP5292390B2 (sl)
KR (1)	KR20100049644A (sl)
CN (1)	CN101821235B (sl)
AR (1)	AR067823A1 (sl)
AU (1)	AU2008284662B2 (sl)
BR (1)	BRPI0814957B8 (sl)
CA (1)	CA2695852C (sl)
CL (1)	CL2008002313A1 (sl)
CO (1)	CO6160326A2 (sl)
CR (1)	CR11266A (sl)
CY (1)	CY1114067T1 (sl)
DK (1)	DK2176220T3 (sl)
DO (1)	DOP2010000053A (sl)
EA (1)	EA017429B1 (sl)
ES (1)	ES2406685T3 (sl)
GE (1)	GEP20125571B (sl)
HR (1)	HRP20130374T1 (sl)
JO (1)	JO2864B1 (sl)
MA (1)	MA31639B1 (sl)
ME (1)	ME01579B (sl)
MX (1)	MX2010001484A (sl)
MY (1)	MY159910A (sl)
NZ (1)	NZ583624A (sl)
PE (1)	PE20090899A1 (sl)
PL (1)	PL2176220T3 (sl)
PT (1)	PT2176220E (sl)
RS (1)	RS52812B (sl)
SI (1)	SI2176220T1 (sl)
TN (1)	TN2010000062A1 (sl)
TW (1)	TWI418543B (sl)
WO (1)	WO2009020234A2 (sl)
ZA (1)	ZA201001289B (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GEP20125571B (en) *	2007-08-07	2012-07-10	Takeda Pharmaceutical	Pyrrolidin-2-one derivatives as androgen receptor modulators
BRPI0907844B8 (pt) *	2008-02-22	2021-05-25	Radius Health Inc	compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en)	2008-02-22	2012-09-18	Radius Health, Inc.	Selective androgen receptor modulators
UY31736A (es) *	2008-03-26	2009-11-10	Takeda Pharmaceutical	Derivados sustituidos de pirazol y su uso
US8987319B2 (en)	2010-02-04	2015-03-24	Radius Health, Inc.	Selective androgen receptor modulators
PT2568806T (pt)	2010-05-12	2016-08-05	Radius Health Inc	Regimes terapêuticos
US8642632B2 (en)	2010-07-02	2014-02-04	Radius Health, Inc.	Selective androgen receptor modulators
WO2012047617A1 (en) *	2010-09-28	2012-04-12	Radius Health, Inc.	Selective androgen receptor modulators
WO2013152170A1 (en) *	2012-04-04	2013-10-10	Catylix, Inc.	Selective androgen receptor modulators
ES2689906T3 (es)	2012-08-09	2018-11-16	Dynamis Therapeutics, Inc.	Meglumina para reducir los niveles altos de triglicéridos
EP2898045B1 (de) *	2012-09-21	2018-10-24	Merck Patent GmbH	Verbindungen mit einer c-c-dreifachbindung und deren verwendung in flüssigkristallmischungen
PL3122426T3 (pl)	2014-03-28	2023-05-15	Duke University	Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
US9421264B2 (en)	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) *	2014-04-24	2016-02-24	동아에스티 주식회사	옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) *	2014-05-06	2016-04-20	成都安斯利生物医药有限公司	一种制备3,5-二氟-4-甲基苯硼酸的方法
SMT202200199T1 (it)	2016-06-22	2022-07-21	Ellipses Pharma Ltd	Metodi di trattamento del cancro del seno ar+.
EP4374925A3 (en)	2017-01-05	2025-01-15	Radius Pharmaceuticals, Inc.	Polymorphic forms of rad1901-2hcl
CN112423844B (zh)	2018-07-04	2024-08-13	雷迪厄斯制药公司	Rad1901-2hcl的多晶型形式
MX2021008364A (es)	2019-01-11	2021-08-05	Gruenenthal Gmbh	Amidas de pirrolidina iii sustituidas.
CN119390714A (zh)	2019-02-12	2025-02-07	雷迪厄斯制药公司	方法和化合物
CN110204505B (zh) *	2019-05-31	2023-02-03	荆门医药工业技术研究院	(s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) *	2019-11-20	2023-01-19	Medshine Discovery Inc.	Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4141399A1 (de)	1991-12-16	1993-06-17	Bayer Ag	4-(substituierte)amino-3-arylpyrrolinon-derivate
PL346795A1 (en) *	1998-09-22	2002-02-25	Yamanouchi Pharma Co Ltd	Cyanophenyl derivatives
US6258833B1 (en)	1999-12-23	2001-07-10	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en)	2000-08-24	2006-04-11	University Of Tennessee Research Foundation	Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) *	2000-09-08	2002-03-27	Yamanouchi Pharmaceut Co Ltd	抗アンドロゲン剤
FR2817472B1 (fr)	2000-12-06	2003-01-03	Oreal	Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
CA2469340A1 (en)	2001-12-06	2003-06-19	Gtx Inc.	Treating muscle wasting with selective androgen receptor modulators
AU2002367424A1 (en) *	2001-12-28	2003-07-24	Takeda Chemical Industries, Ltd.	Androgen receptor antagonists
JP4316232B2 (ja)	2001-12-28	2009-08-19	武田薬品工業株式会社	アンドロゲン受容体拮抗剤
HRP20050038A2 (en)	2002-06-17	2005-08-31	University Of Tennessee Research Foundation	N-bridged selective androgen receptor modulators and methods of use thereof
PL375042A1 (en) *	2002-08-12	2005-11-14	Takeda Pharmaceutical Company Limited	Fused benzene derivative and use
GB0402492D0 (en)	2004-02-04	2004-03-10	Pfizer Ltd	Pharmaceutically active compounds
WO2005090282A1 (en)	2004-03-12	2005-09-29	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
MXPA06013115A (es)	2004-05-11	2007-02-28	Pfizer Prod Inc	Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
WO2005115361A2 (en)	2004-05-17	2005-12-08	Acadia Pharmaceuticals Inc.	Androgen receptor modulators and method of treating disease using the same
MXPA06013958A (es)	2004-06-07	2007-03-15	Univ Tennessee Res Foundation	Moduladores del receptor de androgenos selectivo metodos para utilizar los mismos.
US7585877B2 (en)	2005-01-10	2009-09-08	Acadia Pharmaceuticals, Inc.	Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en)	2005-05-05	2007-07-01	Warner Lambert Co	Androgen modulators
WO2006124447A2 (en)	2005-05-13	2006-11-23	Eli Lilly And Company	Substituted n-arylpyrrolidines as selective androgen receptor modulators
JP5070054B2 (ja)	2005-08-01	2012-11-07	武田薬品工業株式会社	環状アミン化合物
WO2007097289A1 (ja)	2006-02-20	2007-08-30	Takeda Pharmaceutical Company Limited	新規医薬
WO2008011072A2 (en) *	2006-07-19	2008-01-24	Osurf (Ohio State University Research Foundation)	Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
BRPI0715112A2 (pt) *	2006-07-26	2013-10-01	Novartis Ag	inibidores de undecaprenil pirofosfato sintase
WO2008066117A1 (en)	2006-11-30	2008-06-05	Takeda Pharmaceutical Company Limited	Cyclic amine compound
GEP20125571B (en)	2007-08-07	2012-07-10	Takeda Pharmaceutical	Pyrrolidin-2-one derivatives as androgen receptor modulators

2008
- 2008-08-06 GE GEAP200811715A patent/GEP20125571B/en unknown
- 2008-08-06 ME MEP-2013-64A patent/ME01579B/me unknown
- 2008-08-06 JP JP2010504096A patent/JP5292390B2/ja not_active Expired - Fee Related
- 2008-08-06 AR ARP080103428A patent/AR067823A1/es unknown
- 2008-08-06 US US12/672,516 patent/US8420694B2/en not_active Expired - Fee Related
- 2008-08-06 CN CN2008801105925A patent/CN101821235B/zh not_active Expired - Fee Related
- 2008-08-06 NZ NZ583624A patent/NZ583624A/en not_active IP Right Cessation
- 2008-08-06 US US12/221,739 patent/US7834051B2/en active Active
- 2008-08-06 DK DK08792430.4T patent/DK2176220T3/da active
- 2008-08-06 TW TW097129774A patent/TWI418543B/zh not_active IP Right Cessation
- 2008-08-06 HR HRP20130374AT patent/HRP20130374T1/hr unknown
- 2008-08-06 MX MX2010001484A patent/MX2010001484A/es active IP Right Grant
- 2008-08-06 CA CA2695852A patent/CA2695852C/en active Active
- 2008-08-06 AU AU2008284662A patent/AU2008284662B2/en not_active Ceased
- 2008-08-06 BR BRPI0814957A patent/BRPI0814957B8/pt not_active IP Right Cessation
- 2008-08-06 PL PL08792430T patent/PL2176220T3/pl unknown
- 2008-08-06 RS RS20130235A patent/RS52812B/sr unknown
- 2008-08-06 CL CL2008002313A patent/CL2008002313A1/es unknown
- 2008-08-06 ES ES08792430T patent/ES2406685T3/es active Active
- 2008-08-06 PT PT87924304T patent/PT2176220E/pt unknown
- 2008-08-06 WO PCT/JP2008/064500 patent/WO2009020234A2/en not_active Ceased
- 2008-08-06 KR KR1020107005062A patent/KR20100049644A/ko not_active Abandoned
- 2008-08-06 PE PE2008001314A patent/PE20090899A1/es not_active Application Discontinuation
- 2008-08-06 SI SI200830941T patent/SI2176220T1/sl unknown
- 2008-08-06 MY MYPI2010000564A patent/MY159910A/en unknown
- 2008-08-06 EA EA201070246A patent/EA017429B1/ru unknown
- 2008-08-06 EP EP08792430A patent/EP2176220B1/en active Active
- 2008-08-09 JO JO2008353A patent/JO2864B1/en active
2010
- 2010-02-05 DO DO2010000053A patent/DOP2010000053A/es unknown
- 2010-02-05 TN TNP2010000062A patent/TN2010000062A1/fr unknown
- 2010-02-12 CR CR11266A patent/CR11266A/es unknown
- 2010-02-23 ZA ZA2010/01289A patent/ZA201001289B/en unknown
- 2010-02-26 MA MA32657A patent/MA31639B1/fr unknown
- 2010-03-05 CO CO10026475A patent/CO6160326A2/es unknown
2013
- 2013-06-21 CY CY20131100507T patent/CY1114067T1/el unknown

Also Published As

Publication number	Publication date
DK2176220T3 (da)	2013-06-10
MY159910A (en)	2017-02-15
MA31639B1 (fr)	2010-08-02
CN101821235A (zh)	2010-09-01
JO2864B1 (en)	2015-03-15
KR20100049644A (ko)	2010-05-12
ME01579B (me)	2014-09-20
US20110098336A1 (en)	2011-04-28
NZ583624A (en)	2012-06-29
US20090042967A1 (en)	2009-02-12
EA017429B1 (ru)	2012-12-28
AU2008284662B2 (en)	2013-07-25
US7834051B2 (en)	2010-11-16
PT2176220E (pt)	2013-04-09
CL2008002313A1 (es)	2009-05-15
BRPI0814957B1 (pt)	2019-12-03
MX2010001484A (es)	2010-03-04
CO6160326A2 (es)	2010-05-20
TWI418543B (zh)	2013-12-11
CA2695852A1 (en)	2009-02-12
DOP2010000053A (es)	2010-07-15
CR11266A (es)	2010-03-22
GEP20125571B (en)	2012-07-10
TN2010000062A1 (en)	2011-09-26
EP2176220A2 (en)	2010-04-21
CN101821235B (zh)	2012-11-14
EP2176220B1 (en)	2013-03-27
ZA201001289B (en)	2011-04-28
RS52812B (sr)	2013-10-31
WO2009020234A3 (en)	2009-04-16
US8420694B2 (en)	2013-04-16
TW200916439A (en)	2009-04-16
HRP20130374T1 (en)	2013-05-31
EA201070246A1 (ru)	2010-08-30
WO2009020234A2 (en)	2009-02-12
CA2695852C (en)	2017-01-03
ES2406685T3 (es)	2013-06-07
JP2010535704A (ja)	2010-11-25
HK1143972A1 (en)	2011-01-21
JP5292390B2 (ja)	2013-09-18
PL2176220T3 (pl)	2013-08-30
BRPI0814957A2 (pt)	2015-02-03
BRPI0814957B8 (pt)	2021-05-25
CY1114067T1 (el)	2016-07-27
AU2008284662A1 (en)	2009-02-12
PE20090899A1 (es)	2009-08-06
AR067823A1 (es)	2009-10-21

Publication	Publication Date	Title
SI2176220T1 (sl)	2013-05-31	Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev
SI2094658T1 (sl)	2012-04-30	Spojine tetrahidrociklopenta(b)indola kot modulatorji androgenskega receptorja
ZA200906307B (en)	2010-04-28	8-oxy-quinoline derivatives as bradykinin B2 receptor modulators
SI2297100T1 (sl)	2013-02-28	Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja
PT2262785E (pt)	2015-04-29	Derivados de benzofurano, benzotiopeno, benzotiazol como moduladores de fxr
ZA200807551B (en)	2009-06-24	Selective androgen receptor modulators
GB0701992D0 (en)	2007-03-14	Grehlin Receptor Modulators
IL211821A0 (en)	2011-07-31	The compounds as the estrogen related receptors modulators and the uses thereof
ZA201101707B (en)	2012-01-25	Novel imidazolidine compounds as androgen receptor modulators
IL218696A0 (en)	2012-05-31	2-oxo-1- pyrrolidinyl imidazothiadiazole derivatives
ZA201002268B (en)	2011-10-26	Benzothiazoles as ghrelin receptor modulators
IL211822A0 (en)	2011-07-31	The compounds as the estrogen related receptors modulators and the uses thereof
ZA201104069B (en)	2012-02-29	3-aminocyclopentanecarboxamides as chemokine receptor modulators
ZA200806237B (en)	2009-05-27	Cannibinoid receptor modulators
PL2288612T3 (pl)	2015-12-31	Modulatory receptora GABAA
GB0811212D0 (en)	2008-07-23	CB1 Receptor Modulators
ZA200907546B (en)	2010-07-28	New progesterone receptor modulators
PL1991559T3 (pl)	2012-11-30	Pochodne oksy-steroidowe jako selektywne modulatory receptora progesteronu
HK1143376A (en)	2010-12-31	Benzothiazoles as ghrelin receptor modulators
HK1160114A (en)	2012-08-10	Novel imidazolidine compounds as androgen receptor modulators
GB0813350D0 (en)	2008-08-27	Cannabinoid receptor modulators
GB0717998D0 (en)	2007-10-24	Canabinoid receptor modulators
GB0807710D0 (en)	2008-06-04	Receptor and modulators thereof